Fig. 5

Biodistribution, antitumor, and antimetastatic efficacy in vivo. (A) Biodistribution of FEGCG@Cy5-siRNA, FPEI@Cy5-siRNA, and FEGCG/FPEI@Cy5-siRNA 3, and 24 h post-administration. Ex vivo images of major organs and quantitative fluorescence intensity (n = 3). Heart (H), liver (Li), spleen (S), kidney (K), lung (Lu), and tumor (T). (B-C) Treatment schedule and tumor weight after different treatments with saline, FEGCG, FPEI, FEGCG/FPEI NPs, and FEGCG/FPEI@siTOX NPs in subcutaneous tumor model (n = 3). (D-E) Treatment schedule, representative photographs, and H&E staining of liver tissues after different treatments with saline, FEGCG, FPEI, FEGCG/FPEI NPs, and FEGCG/FPEI@siTOX NPs in liver metastasis model (n = 3). (F-G) Quantification of metastatic burden and percent survival rates after different treatments in liver metastasis model (n = 8)